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Introduction: Invasive meningococcal disease (IMD) caused by non-serogroupable (NG) strains mainly af- 
fects immunocompromised individuals. Reduced susceptibility to penicillin in meningococci is increasing 
in Europe but ciprofloxacin resistance remains rare. In 2019, three travel-related meningococcal disease 
cases caused by a ciprofloxacin-resistant NG strain were identified in England, leading Germany to report 
four additional IMD cases (2016 to 2019). We describe these and newly identified cases and characterise 
the strain responsible. 
Methods: Cases were identified as part of national surveillance and by analysing available genomes using 
PubMLST tools. 
Results: Of the cases identified in England in 2019, two geographically distinct cases developed conjunc- 
tivitis after returning from Mecca (Kingdom of Saudi Arabia) and a third linked case presented with IMD. 
Of the four cases from Germany, three occurred in asylum seekers – two familial and a further geograph- 
ically distinct case. Further IMD cases were identified in Italy ( n = 2; 2017–2018), Sweden ( n = 1; 2016) 
and England ( n = 1; 2015). A single ST-175 clonal complex (cc175) strain with genosubtype P1.22–11,15–25 
was responsible. Decreased susceptibility to penicillin was widespread with three ciprofloxacin resistant 
subclusters. Constituent isolates were potentially covered by subcapsular vaccines. 
Conclusion: This disease associated NG cc175 strain exhibits resistance to antibiotics commonly used to 
prevent IMD but is potentially covered by subcapsular (meningococcal B) vaccines. 
Crown Copyright © 2020 Published by Elsevier Ltd on behalf of The British Infection Association. 
This is an open access article under the Open Government License (OGL) 
( http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/ ) 
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Neisseria meningitidis is an obligate commensal of the hu-
an nasopharynx and is carried asymptomatically in ∼10% of the
eneral population. 1 Occasionally, invasive strains may penetrate
he mucous membrane and enter the bloodstream to cause life-∗ Corresponding author. 
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icense (OGL) ( http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3hreatening diseases such as meningitis and/or septicaemia. 2 In ad-
ition to invasive meningococcal disease (IMD), which is associated
ith a case fatality rate of 5–10%, 3 , 4 N. meningitidis is also an un-
ommon cause of bacterial conjunctivitis. 5 , 6 
The meningococcal polysaccharide capsule is essential for sur-
ival in the blood of healthy individuals and allows evasion of
omplement-mediated killing and phagocytosis by the host’s im-
une system. 7 Meningococcal strains are classified into serogroups
ased on the composition of their polysaccharide capsule, with
ost invasive disease-causing strains belonging to serogroups A,ection Association. This is an open access article under the Open Government 
/ ) 
576 L. Willerton, J. Lucidarme and H. Campbell et al. / Journal of Infection 81 (2020) 575–584 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I
 
(  
r  
t  
i  
fi  
l  
t  
(  
c  
p  
i  
a  
(  
(  
q  
w  
g
G
 
v  
d
P
 
v  
t  
N
 
t  
a  
m  
i  
d  
d
R
P
 
p  
i  
[  
O  
l  
t  
d  
c  
(  
m  
l  
f  
b
D
i
 
t  
w  B, C, W, X and Y. Unencapsulated or non-serogroupable (NG)
meningococci are mainly associated with a carrier state and very
rarely cause invasive disease in healthy individuals. 8 , 9 Most IMD
due to NG meningococci has been reported among individuals with
hereditary deficiencies of the terminal complement pathway, who
have a 10 0 0 to 10,0 0 0-fold higher risk of IMD than the general
population. 10 Additionally, treatment of immune-mediated con-
ditions such as atypical hemolytic-uremic syndrome (aHUS) and
paroxysmal nocturnal haemoglobinuria (PHN) with terminal com-
plement inhibitors including eculizumab can lead to acquired com-
plement deficiencies, rendering individuals much more susceptible
to IMD. Such individuals may receive meningococcal vaccination
and long-term penicillin prophylaxis. 
In the United Kingdom, third generation cephalosporins are rec-
ommended for treating suspected IMD cases, while ciprofloxacin
is the first-line chemoprophylaxis for preventing secondary cases
among IMD patients and their close contacts. 11 Due to the asso-
ciated high immediate risk of IMD to cases and their close con-
tacts, meningococcal conjunctivitis is also considered an indication
for public health action, including systemic antibiotic treatment for
cases and antibiotic chemoprophylaxis for their close contacts. 12 
Polysaccharide-conjugate vaccines are licensed for serogroups
A, C, W, and Y and subcapsular protein-based vaccines are li-
censed for serogroup B disease (4CMenB and MenB-fHbp). The
antigens of 4CMenB include Neisseria adhesin A (NadA) peptide
8 (variant NadA-2/3; cross-reactive with NadA-1 and NadA-2/3
peptides), factor H-binding protein (fHbp) peptide 1 (variant 1;
cross-reactive with variant 1 peptides), neisserial heparin-binding
antigen (NHBA) peptide 2 (NHBA does not form discrete variant
groups), and outer membrane vesicles containing Porin A (PorA)
subtype P1.4. 13 MenB-fHbp contains fHbp peptides 55 (variant 1;
cross-reactive with variant 1 peptides) and 45 (variant 3; cross-
reactive with variant 2 and 3 peptides). 14 These sub-capsular
antigens elicit immune responses independently of the capsular
polysaccharide and, therefore, may protect against unencapsulated
meningococci. 
In June 2019, three cases of meningococcal disease due to a
NG ciprofloxacin-resistant strain (P1.22–11,15–25: ST-175 (cc175)
associated with recent travel to Mecca, Kingdom of Saudi Arabia
(KSA), were identified through national surveillance in England. 15 
Following a public health announcement, the Public Health Eng-
land Meningococcal Reference Unit was contacted by the Institute
for Hygiene and Microbiology, University of Würzburg in Germany
about four cases of invasive disease yielding similar isolates during
2016 to 2019, three of which were also ciprofloxacin-resistant. 
This study aimed to describe these and newly identified cases
identified through genomic analysis of available cc175 genomes.
We also aimed to characterise the strain responsible in terms of
geo-temporal distribution, antibiotic resistance determinants and
potential vaccine coverage. 
Materials and methods 
Case identification 
IMD cases were identified as part of national surveillance in the
respective countries, where isolates are submitted to the national
reference laboratory for confirmation and characterisation. 16 , 17 
Antibiotic susceptibility testing 
Antibiotic susceptibility testing was performed using antibiotic
gradient strip diffusion methods (Etest, bioMérieux UK Limited,
Basingstoke or MIC test strips, Liofilchem, Italy). The resulting min-
imum inhibitory concentration (MIC) values were interpreted ac-
cording to the European Committee on Antimicrobial Susceptibility
Testing (EUCAST; v9.0; 2019–01–01). dentification of cc175 and potentially closely-related genomes 
Genomes were obtained from the PubMLST Neisseria database
pubmlst.org/neisseria) and two currently unpublished UK car-
iage collections 18 , 19 In the first instance we aimed to cap-
ure all cc175 and potentially closely-related genomes, includ-
ng those with incomplete Multilocus Sequence Type (MLST) pro-
les or clonal complex-unassigned sequence types containing at
east three ST-175 ML ST alleles. ML ST data were exported from
he PubMLST Neisseria database for all available genomes > 2 Mb
 n = 19,802, accessed 22 October 2019). These included n = 62
c175 genomes. Genomes assigned to non-cc175 clonal com-
lexes were removed from the dataset ( n = 14,181). The remain-
ng genomes comprised those with sequence types unassigned to
 clonal complex ( n = 5240) and those with incomplete profiles
 n = 381). Among these, genomes which had three ST-175 alleles
 n = 11) were retained and the rest were discarded. Genome se-
uence data of additional cc175 isolates from UK carriage studies
ere also included in the analysis ( n = 6), resulting in a total of 79
enomes for phylogenetic analysis (Supplementary table). 
enotypic data 
Genotypic data for antibiotic resistance determinants and MenB
accine antigens were exported from the PubMLST Neisseria
atabase using the ‘export dataset’ function. 
hylogenetic analyses 
Core genome (1605 loci) comparisons ( N. meningitidis cgMLST
1.0) were performed using the PubMLST genome compara-
or tool. 20 The resulting distance matrices were visualised as
eighbor-Net networks using SplitsTree4 (version 4.13.1). 21 
The sequences of all known gyrA alleles were downloaded from
he PubMLST database ( n = 379, accessed 13 May 2020). All gyrA
lleles were imported into BioEdit, 22 where a ClustalW align-
ent was performed. A Neighbor-Joining tree was created us-
ng MEGA4. 23 Clades were annotated by species according to the
istribution of the respective alleles on the PubMLST Neisseria
atabase (accessed 13 May 2020). 
esults 
hylogenetic analysis of cc175 
Of the 79 genomes that underwent phylogenetic analyses (sup-
lementary Table 1), 68 were assigned to cc175 while the remain-
ng 11 were either unassigned to a cc (ST-4051 [ n = 6], ST-6525
 n = 2], ST-5540 [ n = 1]), or had incomplete MLST profiles ( n = 2).
n a phylogenetic network ( Fig. 1 ), the ST-4051 and ST-5540 iso-
ates and the two isolates with incomplete MLST profiles were dis-
inct from the cc175 isolates and were disregarded for the remain-
er of the analyses. The remaining genomes ( n = 70), including the
c-unassigned ST-6525 genomes, formed six distinct sublineages
arbitrarily named sublineage 1 to sublineage 6) ( Fig. 1 ; supple-
entary Table 1) and included carriage and disease isolates be-
onging to multiple serogroups and collected in 15 countries on
our continents (Africa, North America, South America and Europe)
etween 20 0 0 and 2019 ( Fig. 2 , supplementary Table 1). 
istribution and characteristics of English, German and related case 
solates: sublineage 1 – the NG cc175 sublineage 
Isolates from the known English and German cases belonged
o sublineage 1 (referred to here as the NG cc175 sublineage)
hich comprised n = 31 NG isolates from Europe and Africa
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Non-cc175 genomes
cc175 genomes sublineages 1-6
ST-6525 genomes
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Fig. 1. Population structure of ST-175 complex and closely related genomes. 
Neighbor-Net phylogenetic network based on a comparison of 1605 core genome loci among cc175 ( n = 68), ST-6525 (cc-unassigned; n = 2) and closely related non-cc175 
isolates ( n = 9). Several sublineages were identified among cc175 genomes, labelled 1–6. The scale bar indicates the number of different loci among the 1605 that were 
compared. 
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Fig. 2. Geo-temporal, serogroup and disease/carrier status distribution of ST-175 complex and ST-6525 isolates identified from 20 0 0 to 2019. 
Neighbor-Net phylogenetic network based on a comparison 1605 core genome loci among cc175 ( n = 68), ST-6525 ( n = 2) and distinct non-cc175 isolates ( n = 9, not shown 
individually). The scale bar indicates the number of different loci among the 1605 that were compared. 
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t  (2014–2019) arranged in several clusters (clusters A to E and a sin-
gleton; Table 1 ; Fig. 3 ). These included four newly identified in-
vasive isolates from England ( n = 1; 2015), Italy ( n = 2; 2017 and
2018) and Sweden ( n = 1; 2016). 
All of the disease isolates in the NG cc175 sublineage (invasive
and conjunctivitis) possessed PorA genosubtype P1.22–11,15–25.
Some carrier isolates differed in their PorA VR2 (P1.15–56 or P1.15–
75). All of the NG cc175 sublineage isolates possessed penA alle-
les associated with reduced susceptibility to penicillin and, where
known, this was reflected in their penicillin MICs ( Table 1 ). Several
clusters/subclusters possessed gyrA alleles with mutations associ-ted with ciprofloxacin resistance and, where known, this was re-
ected in their MICs ( Table 1 ). All Sublineage 1 isolates possessed
llele 583 for DNA topoisomerase IV subunit A ( parC; NEIS1525) . 
G cc175 sublineage case descriptions 
The English cases from 2019 (cluster A) included two geograph-
cally distinct cases presenting with conjunctivitis upon return-
ng from Mecca (for Umrah) whilst the third case, who did not
ravel but belonged to the same mosque community as one of
he other cases, went on to develop IMD. The latter case was
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Table 1 
Characteristics of cc175 sublineage 1 isolates: the non-groupable cc175 sublineage isolates and additional details surrounding those identified in immunocompromised patients. 
Cluster 
PubMLST 
ID Year Country Disease 
Immunocomprimised? 
(if invasive) gyrA allele 
Ciprofloxacin 
MIC (mg/L) penA allele 
Penicillin MIC 
(mg/L) PorA VR2 
fHbp 
variant 
fHbp 
peptide 
NHBA 
peptide 
A 93631 2017 Germany Invasive NK 12 0.003 662 0.25 15–25 1 321 9 
84075 2017 Italy Invasive NK 12 0.004 662 0.125 15–25 1 321 9 
91539 2018 Italy Invasive NK 12 0.006 662 0.25 15–25 1 321 9 
89565 2019 England Conjunctivitis n/a 313 e 0.12 662 0.25 15–25 3 111 9 
89712 2019 England Conjunctivitis n/a 313 e 0.12 662 0.25 15–25 3 111 9 
89713 2019 England Invasive Complement 
deficiency 
313 e 0.12 662 0.25 15–25 3 111 9 
93679 2019 Germany Invasive Plasmacytoma 313 e 0.064 662 0.19 15–25 3 111 9 
B 93629 2016 Germany Invasive Terminal complement 
deficiency 
187 f 0.094 909 0.25 15–25 2 151 9 
93630 2016 Germany Invasive Terminal complement 
deficiency 
187 f 0.064 909 0.5 15–25 2 151 9 
42784 2016 Sweden Invasive Pregnant 187 f 0.094 662 0.094 15–25 2 151 9 
C 41896 g 2014 Ethiopia Carrier n/a 12 0.004 662 0.25 15–56 2 151 1578 b 
41897 g 2014 Ethiopia Carrier n/a 12 0.004 662 0.25 15–56 2 151 1578 b 
42666 h 2014 Ethiopia Carrier n/a 12 0.004 662 0.25 15–56 2 151 9 
42668 h 2014 Ethiopia Carrier n/a 12 0.002 662 0.25 15–56 2 151 9 
60134 2014 Ethiopia Carrier n/a 12 0.002 662 0.25 15–25 2 151 9 
60143 2014 Ethiopia Carrier n/a 12 0.004 662 0.25 15–56 2 151 9 
60308 2014 Ethiopia Carrier n/a 12 0.002 662 0.125 15–56 2 151 9 
61207 2014 Ethiopia Carrier n/a 12 NK 662 NK 15–56 2 151 9 
D 49960 2015 England Carrier n/a 12 NK 662 NK 15–25 2 151 9 
50082 2015 England Carrier n/a 12 NK 662 NK 15–25 2 151 9 
52614 2015 England Carrier n/a 12 NK 662 NK 15–25 2 151 9 
52715 2015 England Carrier n/a 12 NK 662 NK 15–25 2 151 9 
88632 2018 England Carrier n/a 12 NK 662 NK 15–25 2 151 9 
E 52572 2015 Wales Carrier n/a 152 c NK 662 NK 15–25 1 321 9 
41727 2016 France Carrier n/a 152 c 0.125 662 NK 15–25 1 321 9 
47101 2016 Italy Carrier n/a 152 c NK 662 NK 15–25 1 321 9 
47115 2016 Italy Carrier n/a 152 c NK 662 NK 15–25 1 321 9 
84968 2018 Norway Carrier n/a 12 NK 662 NK 15–25 1 321 9 
85033 2018 Norway Carrier n/a 12 NK 662 NK 15–25 1 321 9 
92641 2019 Norway Carrier n/a 12 NK 662 NK 15–75 1 321 9 
S a 41526 2015 England Invasive No i 12 0.004 662 0.19 15–25 2 151 9 
All isolates in table 1 were ST-175 with parC allele 583 and nadA allele 311 (NadA peptide 0). 
a Singleton. 
b 1 bp different from nhba allele 7. 
c Mutation D95N. 
e Mutations A69S, T91I, N103D, I111V, V120I, D210E. 
f Mutations T91I, N103D, I111V, V120I, V199I, D210E 
g/h One of two isolates from a single person 8 weeks apart. 
i the following were ruled out - inherited complement deficiencies, complement deficiencies due to glomerulonephritis, vasculitis or Eculizumab therapy, asplenia, splenic dysfunction and HIV. NK = not known. 
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A
B
C
D
E
gyrA313 gyrA152
gyrA187
England (2015-2019)
Ethiopia (2014)
France (2016)
Germany (2016-2019)
Italy (2016-2018)
Norway (2018-2019)
Sweden (2016)
Wales (2015)
Disease
Carriage (no outline)
Sublineage 1 Clusters A-E
Remainder of cc175
Fig. 3. Population structure and geo-temporal, disease/carrier status and ciprofloxacin resistance-associated gyrA allele distribution of isolates belonging to the non-groupable 
cc175 sublineage. 
Neighbor-Net phylogenetic network based on a comparison 1605 core genome loci among cc175 sublineage 1 (the non-groupable cc175 sublineage), isolates ( n = 31). The 
sublineage contained several clusters labelled A-E and a singleton. The scale bar indicates the number of different loci among the 1605 that were compared. The reference 
strain (remainder of cc175) was 40,593. 
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(  confirmed as being complement deficient. All three case isolates
were ciprofloxacin resistant ( gyrA allele 313). A fourth, newly iden-
tified, English IMD case from 2015 did not belong to any cluster
(singleton). The isolate was susceptible to ciprofloxacin ( gyrA al-
lele 12). The patient had no inherited complement deficiencies or
complement deficiencies due to glomerulonephritis, vasculitis or
Eculizumab therapy and did not have asplenia, splenic dysfunction
or HIV. 
The four German IMD cases occurred in 2016 ( n = 2), 2017
( n = 1) and 2019 ( n = 1). The 2016 cases (cluster B) occurred in
Afghan asylum seekers who were siblings with confirmed terminal
complement deficiency. Both yielded ciprofloxacin resistant iso-
lates ( gyrA allele 187). The 2017 case (cluster A) was geographi-
cally distinct and occurred in an asylum seeker from Nigeria. Themmune status of this patient was not known. The case isolate
as ciprofloxacin sensitive ( gyrA allele 12). The 2019 case (clus-
er A) was a cancer patient and the corresponding isolate was
iprofloxacin resistant ( gyrA allele 313). 
Among the other IMD cases, details of the Italian cases (2017
nd 2018; both cluster A) including immune status and back-
round were unknown. Both isolates were ciprofloxacin sensitive
 gyrA allele 12). The Swedish case (2016; cluster B) was pregnant
nd the corresponding isolate was ciprofloxacin resistant ( gyrA
llele 187). 
The remaining sublineage 1 isolates (clusters C, D and E) were
arrier isolates from England ( n = 5; 2015 to 2018), Ethiopia ( n = 8;
014), Italy ( n = 2; 2016), Norway ( n = 3; 2018 to 2019), France
 n = 1; 2016) and Wales ( n = 1; 2015). All possessed gyrA allele
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r  2 with the exception of a cluster E subcluster, comprising iso-
ates from Italy ( n = 2; 2016), France ( n = 1; 2016) and Wales ( n = 1;
015), with the ciprofloxacin resistance-associated gyrA allele 152.
his was reflected in MIC values, where known ( Table 1 ). 
ther cc175 sublineages - Sublineages 2 to 6 
cc175 sublineages 2–6 included geo-temporally diverse inva-
ive disease and carrier isolates collected in Africa, South Amer-
ca, North America and Europe in 20 0 0–2018 ( Fig. 2 ). All iso-
ates in sublineages 2–6 possessed gyrA allele 12 associated with
iprofloxacin sensitivity. 
utative origins of ciprofloxacin resistance determinants 
The ciprofloxacin resistance-associated alleles observed among
G cc175 sublineage isolates (alleles gyrA313, gyrA187 and gyrA152 )
ell into two main clades corresponding to N. meningitidis and
. cinerea ( Fig. 4 ). The gyrA313 and gyrA187 alleles, which were
resent among invasive and conjunctivitis cc175 isolates only, fell
nto the N. cinerea cluster. Allele gyrA152 which was present among
arrier cc175 isolates only, fell into the N. meningitidis clade. 
otential subcapsular (MenB) vaccine coverage of the NG cc175 
ublineage 
The NG cc175 isolates did not possess alleles for PorA P1.4 and
ere unable to express NadA due to an interruption of the nadA
llele (allele 311) with insertion sequence IS 1301 . All isolates pos-
essed nhba alleles for either peptide 9 ( n = 29) or peptide 1578
 n = 2). Ten of the 31 NG cc175 isolates, including 3/9 invasive iso-
ates, possessed fHbp variant 1 alleles (peptide 321). The remainder
ll had fHbp variant 2 alleles ( n = 17; peptide 151) or fHbp variant
 alleles ( n = 4, peptide 111) ( Table 1 ). 
iscussion 
Since 2015, a single NG cc175 strain (the NG cc175 sublineage)
as caused nine IMD and two conjunctivitis cases in Europe. Seven
f these (2x conjunctivitis and 5x IMD) were due to ciprofloxacin
esistant isolates with one of two distinct gyrA alleles of N. cinerea
rigin, thus highlighting the significance of natural transformation
mong Neisseria species in the continued emergence of antibiotic
esistance. 24 Horizontal gene transfer occurs more readily between
losely related bacteria. 25 That these resistance-associated gyrA al-
eles from N. cinerea have established a stable presence within per-
istent cc175 sublineages is a concern since they may also now
e more readily transferred to other, more virulent, meningococ-
al strains. A further subpopulation comprising only carriage iso-
ates possessed a distinct ciprofloxacin resistance-associated gyrA
llele of meningococcal origin. None of the other five di verse cc175
ublineages included any isolates with ciprofloxacin resistance-
ssociated alleles. It not known whether the existence of sev-
ral distinct resistance-associated alleles in just a single sublineage
arks a propensity for acquiring/maintaining antibiotic resistance
r just opportunism. The fact that the affected sublineage is non-
roupable is probably just a coincidence however, as the corre-
ponding isolates share alterations in over 100 other genes com-
ared to the isolates in the other sublineages. The loss of a capsule
s therefore one of over 100 changes that might influence their ap-
arent shared propensity to acquire resistance. 
Three of the IMD cases were related to travel to Mecca, KSA for
he Umrah pilgrimage that takes place throughout the year. A fur-
her three were from asylum seekers who may also travel long dis-
ances and encounter crowded conditions that are known to prop-
gate the spread of meningococcal carriage. 26–28 Thus, although alline invasive cases occurred in Europe, this strain is clearly present
eyond Europe, where further cases may have occurred. The es-
ablishment of a Global Meningitis Genome Partnership 29 as part
f the WHO-led ‘Global Roadmap to Defeat Meningitis by 2030 ′ 30 
s intended to facilitate the participation of all nations in genomic
urveillance and thus enhance the scope of similar investigations.
he annual Hajj pilgrimage to Mecca has previously been asso-
iated with outbreaks of meningococcal disease. 31–33 Since vacci-
ation of all travellers to KSA with the MenACWY polysaccharide
accine became mandatory in 2002, no pilgrimage-associated IMD
utbreaks have been reported. 34 Unconjugated polysaccharides do
ot prevent the acquisition of carriage, 35–37 however, and would
ot be expected to prevent disease caused by a NG strain such as
he NG cc175 sublineage. 38 
Ciprofloxacin prophylaxis is mandatory for pilgrims travelling to
he KSA from high-risk sub-Saharan African meningitis belt coun-
ries. This will be ineffective against ciprofloxacin resistant mem-
ers of the NG cc175 sublineage and may even have had a role in
ts propagation. 39 , 40 Approximately 1.5 million doses are estimated
o have been given to travellers over the past decade. 41 The bene-
ts of its continued use have, however, been challenged, given the
otential contribution in the emergence of ciprofloxacin resistance
mong meningococci. 42 The findings of a recent study by Cold-
ron and colleagues showed possible benefits of using ciprofloxacin
s prophylaxis in outbreak situations in the meningitis belt. 43 The
ndings of the present study serve to highlight the importance of
ntibiotic susceptibility testing at the earliest opportunity to en-
ure that such interventions are not compromised. 
While NG meningococci rarely cause IMD among healthy indi-
iduals, they may cause invasive disease in immunocompromised
ndividuals, particularly those with inherited or acquired deficien-
ies of the terminal complement pathway, some of which have
een fatal. 44 Accordingly, among the nine IMD cases caused by the
G cc175 sublineage, at least five had an immune deficiency. Some
mmunocompromised individuals, e.g. those with terminal comple-
ent deficiencies, are recommended to receive MenACWY conju-
ate and subcapsular (MenB) vaccines. Only the latter may provide
rotection against the NG cc175 sublineage. Protection by protein-
ased subcapsular vaccines depends on adequate cross-reactivity
nd surface expression of at least one vaccine antigen. According
o the genetic Meningococcal Antigen Typing System (gMATS), 45 
 genetic tool for predicting 4CMenB strain coverage, the cover-
ge afforded by both the predominant NHBA peptide (peptide 9)
nd, where present, fHbp variant 1 peptide (peptide 321), is unpre-
ictable. In the case of NHBA, this reflects the scarcity of peptide 9
ithin the original gMATS dataset. 45 Unfortunately, the phenotypic
recursor, MATS, 46 is only validated for MenB isolates. Nonethe- 
ess, the effectiveness of vaccination in the absence of a working
omplement system is uncertain and IMD cases have occurred in
accinated individuals with complement deficiency. 47 
In addition to vaccination, some countries, e.g. the UK and
rance, recommend antibiotic chemoprophylaxis for individuals
ith terminal complement deficiencies. 44 The antibiotic of choice
s usually penicillin but penicillin-resistant strains have been re-
orted to cause IMD in this group. 47 , 48 Whilst penicillin resis-
ance amongst N. meningitidis is relatively uncommon, isolates dis-
laying reduced susceptibility are becoming increasingly reported
orldwide. 49–51 This has been associated with amino acid substi-
utions in the Penicillin Binding Protein 2 encoded by the penA
ene 49 all of which were observed among the NG cc175 sublin-
age isolates. As such, this strain may be particularly dangerous for
hese individuals. It is noteworthy that the corresponding penicillin
ICs were relatively low (mainly 0.25 mg/L). The EUCAST break-
oint for penicillin resistance in meningococci is 0.25 mg/L, how-
ver, based on experimental work in mice and penicillin levels
eached in the cerebrospinal fluid during treatment, a breakpoint
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N. meningitidis cluster
N. meningitidis: n=15,906
N. subflava: n= 1
gyrA152
N. cinerea cluster
N. meningitidis: n= 26 (10 alleles)
N. cinerea: n= 32 (23 alleles)
gyrA187
gyrA313
Fig. 4. Phylogenetic analysis of gyrA alleles ( n = 379) highlighting those identified among isolates belonging to the non-groupable cc175 sublineage. 
Neighbor-Joining tree of nucleotide sequences of 379 gyrA alleles on PubMLST (accessed 13/05/2020). The non-groupable cc175 sublineage alleles (alleles 152, 187 and 313) 
were distributed between clades predominantly representing N. cinerea and N. meningitis . The Tree was constructed using MEGA4. The scale bar represents the number of 
nucleotide differences. 
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 f 1 mg/L has been proposed. 52 Nonetheless, one of two of the in-
asive cc175 isolates with the rarer penA allele ( penA909 ) had an
IC of 0.5 mg/L – the same as that of a previous breakthrough
train in a patient on long term penicillin prophylaxis. 48 Thus, it
hould be considered that low level prophylactic dosing may be
ess effective than therapeutic doses. 
Ciprofloxacin resistance in meningococci is rare in most coun-
ries and is mainly associated with sporadic cases, apart from an
utbreak that occurred in India in 2005 53 and in China where it
s prevalent. 54 , 55 Ciprofloxacin resistance among N. meningitidis is
ue to altered gyrA genes (encoding DNA gyrase), 56–58 as observed
mong the NG cc175 sublineage. Mutations in the parC gene (en-
oding DNA topoisomerase IV subunit A) have also been associ-
ted with increased ciprofloxacin resistance when in combination
ith gyrA mutations, though this was not observed in this study. 24 
eningococcal resistance to ciprofloxacin is concerning because it
s currently the chemoprophylaxis of choice for close contacts of
MD cases. It may also be prescribed for prophylaxis 59–61 or res-
ue therapy for febrile illnesses in patients with complement defi-
iency, 62 thus adding to concerns surrounding the NG cc175 sub-
ineage with regards to complement deficient patients. 
In conclusion, we identified a NG ciprofloxacin-resistant
eningococcal strain belonging to cc175 that has recently caused
ultiple cases of meningococcal disease across Europe. The NG
c175 sublineage is particularly virulent for immunocompromised
ndividuals, including those that may be less well protected by
accination. Current antibiotic prophylaxis regimes may also be
ubverted. Clinicians should remain vigilant when presented with
eningococcal disease among pilgrims, asylum seekers or those
ith immunodeficiencies to ensure appropriate treatment of the
ase and their close contacts. Continued surveillance of antibiotic
esistance among meningococci is essential to identify and monitor
uch threats and to explore the possibility of alternative chemopro-
hylactic agents such as azithromycin, 63 especially for complement
eficient individuals already at increased risk of developing IMD. 
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